Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
NCT02408536 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2023-03-24
Summary
The purpose of this study is to retrospectively evaluate treatments and outcomes of patients with low grade serous ovarian carcinomas in Italy.
Conditions
- Low-grade Serous Ovarian Carcinoma
- Recurrent Invasive Borderline Serous Ovarian Cancer
Sponsors & Collaborators
-
National Cancer Institute, Naples
lead OTHER
Principal Investigators
-
Sandro Pignata, MD PhD · NCI Naples
-
Chiara Della Pepa, MD · NCI Naples
-
Francesco Perrone, MD PhD · NCI Naples
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-10-31
- Primary Completion
- 2023-12-31
- Completion
- 2024-07-31
Countries
- Italy
Study Locations
More Related Trials
-
Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France
NCT05204342 ·Status: COMPLETED
-
Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer
NCT06775470 ·Status: RECRUITING
-
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
NCT05574673 ·Status: RECRUITING
-
Study of Predictive Factors of Chemoresistance in Ovarian Cancer
NCT02878122 ·Status: COMPLETED
-
An INternational Frontline Ovarian Cancer Real World Management Study
NCT04460768 ·Status: COMPLETED
-
Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer
NCT00660842 ·Status: UNKNOWN ·Phase: PHASE3
-
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941 ·Status: COMPLETED
-
Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology
NCT07167433 ·Status: RECRUITING
-
Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation
NCT05763472 ·Status: UNKNOWN
-
Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK
NCT04532645 ·Status: COMPLETED
-
Centralization and Oncologic Outcomes in Ovarian Cancer
NCT07075939 ·Status: ACTIVE_NOT_RECRUITING
-
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
NCT01422265 ·Status: COMPLETED
-
OSCA - Olaparib Standard of CAre Study
NCT02262273 ·Status: COMPLETED
-
Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario
NCT06836219 ·Status: RECRUITING
-
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
NCT06907771 ·Status: RECRUITING
-
Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer
NCT06535334 ·Status: NOT_YET_RECRUITING
-
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
NCT05410015 ·Status: RECRUITING
-
Survival Outcomes of Ovarian Malignancies in Chinese Population
NCT03291262 ·Status: UNKNOWN
-
Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125
NCT02247323 ·Status: UNKNOWN
-
Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.
NCT04573933 ·Status: COMPLETED
-
PRO for Fighting FT in Ovarian Cancer
NCT06032975 ·Status: RECRUITING
-
Prognostic and Predictive Biomarkers in Ovarian Cancers
NCT03010124 ·Status: RECRUITING ·Phase: NA
-
Ribociclib and Letrozole Treatment in Ovarian Cancer
NCT03673124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Circulating Tumoral DNA in Ovarian Cancer
NCT01350908 ·Status: COMPLETED ·Phase: NA
-
Letrozole in Patients With Ovarian Tumors
NCT00505661 ·Status: TERMINATED ·Phase: PHASE2